Preclinical relaxin therapy to reverse cardiac fibrosis and gain functional benefits

临床前松弛素疗法可逆转心脏纤维化并获得功能益处

• 批准号: nhmrc : GNT1081710
• 负责人: A/Pr XiaoJun Du
• 金额: $ 70.26万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2015
• 资助国家: 澳大利亚
• 起止时间: 2015-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/preclinical-relaxin-therapy-functional-benefits/1345412
• 关键词: Preclinical; relaxin; therapy; reverse; cardiac

Cardiac fibrosis is a key factor promoting heart disease and onset of complications including arrhythmias and heart failure. There is urgent and unmet need of drugs that can reverse fibrosis. By documenting anti-fibrotic action of a peptide hormone relaxin, CIA and his team will test therapeutic effect of relaxin in heart disease models focusing on fibrosis-reversal and functional gain, particularly arrhythmias. This work would promote development of relaxin as a new cardiovascular drug.

心脏纤维化是促进心脏病和心律失常、心力衰竭等并发症发生的关键因素。目前对逆转纤维化的药物的需求迫切且尚未得到满足。通过记录一种肽激素松弛素的抗纤维化作用，CIA和他的团队将在心脏病模型中测试松弛素的治疗效果，重点是纤维化逆转和功能增加，特别是心律失常。这项工作将促进舒张素作为一种新型心血管药物的开发。